Sequana Medical NV is a commercial stage medical device company with headquarters in Ghent, Belgium and offices in Zurich, Switzerland. At Sequana Medical, we are committed to helping patients suffering from fluid overload due to liver disease, cancer and heart failure. Sequana Medical’s technology is based on its proprietary alfapump® platform which is applicable across multiple life-threatening disorders.
We embrace diversity and inclusion. You will have the opportunity to work with outstanding business teams and contribute to the success of the company. We strive to provide all our employees with the means to develop their skills and experiences, at every level.
Sequana Medical is hiring a part-time corporate legal and administrative assistant to the CFO and IR.
We offer a part-time contract in a very dynamic and international environment with an attractive
salary package. If you are interested, please click the button below and complete the requested form.
Apply now
Estes et al. (2018)
Estes et al. (2018)
Estes et al. (2018)
Estes et al. (2018)
De alfapump® is nog steeds in klinisch onderzoek in de VS en Canada en daarom zijn alle uitspraken met betrekking tot veiligheid en werkzaamheid niet van toepassing in deze gebieden.
De DSR-therapie is nog in ontwikkeling en het moet worden opgemerkt dat alle uitspraken met betrekking tot veiligheid en werkzaamheid voortkomen uit lopend preklinisch en klinisch onderzoek dat nog moet worden voltooid.
Er is geen verband tussen de DSR-therapie en lopende onderzoeken met het alfapump® systeem in Europa, de VS en Canada.
Testani JM, Hanberg JS, Cheng S, et al. Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure. Circulation Heart failure. 2016;9(1):e002370. doi:10.1161/CIRCHEARTFAILURE.115.002370.
Kilgore et al. (2017); Ambrosy et al. (2014)
Kilgore et al. (2017)
Costanzo et al. (2007)
Benjamin et al. (2013)
Ayantunde et al. (2006)
Wereldgezondheidsorganisatie Internationaal Agentschap voor Kankeronderzoek 2018 (http://gco.iarc.fr/today/home) (geschat aantal nieuwe borst- en eierstokkankers in 2018 (bruto cijfer))
Europese Vereniging voor Leveronderzoek EASL richtlijnen klinische praktijk voor het beheer van ascites, spontane bacteriële buikvliesontsteking en hepatorenaal syndroom bij cirrose. Journel of Hepatology. 2010 vol. 53. 397-417. p. 402.
Ginès et al. (2004) (verklarende dat refractaire ascites zich voordoet bij 5 tot 10 procent van de patiënten met ascites)
Runyon et al. (2009)
GlobalData NASH Epidemiology Forecast to 2026
U.S. Centers for Disease Control and Prevention, Health, United States 2016, Chartbook on Long-term trends in Health, Table 20 (website)
In den USA und Kanada befindet sich der alfapump® derzeit noch in der klinischen Erprobung. Daher sind Aussagen zur Sicherheit und Wirksamkeit in diesen Gebieten nicht anwendbar.
Die DSR-Therapie befindet sich noch in der Entwicklung, und es sollte beachtet werden, dass Aussagen zur Sicherheit und Wirksamkeit aus laufenden vorklinischen und klinischen Untersuchungen stammen, die noch nicht abgeschlossen sind.
Es besteht kein Zusammenhang zwischen der DSR-Therapie und laufenden Untersuchungen mit dem alfapump®-System in Europa, den USA und Kanada.
Testani JM, Hanberg JS, Cheng S, et al. Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure. Circulation Heart failure. 2016;9(1):e002370. doi:10.1161/CIRCHEARTFAILURE.115.002370.
Kilgore et al. (2017); Ambrosy et al. (2014)
Costanzo et al. (2007)
Costanzo et al. (2007)
Benjamin et al. (2013)
Ayantunde et al. (2006)
World Health Organization Internationale Agentur für Krebsforschung 2018 (http://gco.iarc.fr/today/home) (geschätzte Anzahl neuer Brust- und Ovarialfälle in 2018 (Bruttoziffer))
European Association for the Study of the Liver. EASL klinische Richtlinien für die Behandlung von Aszites, spontane bakterielle Peritonitis und hepatorenales Syndrom bei Zirrhose. Journel of Hepatology. 2010 Bd. 53. 397-417. S. 402.
Ginès et al. (2004) (mit Angabe, dass refraktärer Aszites bei 5 bis 10 Prozent der Patienten mit Aszites auftritt).
Runyon et al. (2009)
GlobalData NASH Epidemiologie-Prognose bis 2026.
U.S. Centers for Disease Control and Prevention, Health, United States 2016, Chartbook über Langzeit-Trends im Gesundheitswesen, Tabelle 20 (web site)
Testani JM, Hanberg JS, Cheng S, et al. Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure. Informations sur la défaillance cardiaque. 2016;9(1):e002370. doi:10.1161/CIRCHEARTFAILURE.115.002370
Kilgore et al. (2017); Ambrosy et al. (2014)
Kilgore et al. (2017)
Costanzo et al. (2007)
Benjamin et al. (2013)
Ayantunde et al. (2006)
Organisation Mondiale de la Santé Agence Internationale pour la Recherche sur le Cancer 2018 (Visitez le site Internet) (nombre estimé de nouveaux cas de cancer de l’ovaire en 2018 (taux brut))
Association Européenne de l’Étude du Foie. EASL directives de pratique clinique relatives à la gestion d’ascites, de péritonites bactériennes spontanées et du syndrome hépatorénal dans le cadre d’une cirrhose Journal d’hépatologie. 2010 vol. 53. 397-417. p. 402.
The alfapump® fait toujours l’objet d’une étude clinique aux États-Unis et au Canada. Par conséquent, aucun énoncé concernant la sécurité et l’efficacité ne s’applique dans ces territoires.
Le traitement DSR est encore en développement et il convient de noter que toute déclaration concernant la sécurité et l’efficacité découle d’investigations précliniques et cliniques en cours qui n’ont pas encore été complétées.
Il n’y a pas de lien entre le traitement DSR et les investigations en cours avec le système alfapump® en Europe, aux États-Unis et au Canada.
Ginès et al. (2004) (déclarant que l’ascite réfractaire apparaît chez 5 à 10% des patients souffrant d’ascite)
Runyon et al. (2009)
GlobalData NASH Epidemiology Forecast to 2026
U.S. Centers for Disease Control and Prevention, Health, United States 2016, Chartbook on Long-term trends in Health, Table 20 (Visitez le site Internet)
Testani JM, Hanberg JS, Cheng S, et al. Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure. Circulation Heart failure. 2016;9(1):e002370. doi:10.1161/CIRCHEARTFAILURE.115.002370
Kilgore et al. (2017); Ambrosy et al. (2014)
Kilgore et al. (2017)
Costanzo et al. (2007)
Benjamin et al. (2013)
Ayantunde et al. (2006)
World Health Organization International Agency for Research on Cancer 2018 (website) (estimated number of new breast and ovarian cases in 2018 (crude rate))
European Association for the Study of the Liver. EASL clinical practice guideliones on the management of ascites, spontane bacterial peritonitis, and hepatorenal syndrome in cirrhosis. Journel of Hepatology. 2010 vol. 53. 397-417. p. 402
Ginès et al. (2004) (stating refractory ascites occurs in 5 to 10 percent of patients with ascites)
Runyon et al. (2009)
GlobalData NASH Epidemiology Forecast to 2026
U.S. Centers for Disease Control and Prevention, Health, United States 2016, Chartbook on Long-term trends in Health, Table 20 (web site)
The alfapump® is still under clinical investigation in the US and Canada and therefore any statements regarding safety and efficacy do not apply in these territories.
The DSR therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
There is no link between the DSR therapy and ongoing investigations with the alfapump® system in Europe, the US and Canada.
We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our
Privacy & Cookie Policy
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
